Study Finds Antidepressant Effective For Weight Loss In Women.(Brief Article)

2001 OCT 4 - (NewsRx.com & NewsRx.net) --

A drug approved for the treatment of depression and smoking cessation appears effective for long-term weight loss in obese women, according to researchers at Duke University Medical Center, Durham, North Carolina.

The study results, which appear in the September 12, 2001, issue of Obesity Research, show that women who took bupropion (trade name Wellbutrin) combined with a 1,600-calorie per day diet lost significantly more weight than women on placebo and the same diet, and those effects were sustained for up to two years, according to Dr. Kishore Gadde, director of obesity clinical trials at Duke and lead investigator of the study.

Approximately 97 million Americans are estimated to be overweight or obese, according to a 1998 report on obesity published by the National Institutes of Health. "Because of the increasing incidence of obesity worldwide, it is vital to identify new ways of helping people to lose and sustain weight loss," Gadde said. "Obesity carries a tremendous risk of high blood pressure, coronary artery disease, diabetes and a variety of cancers. It is a major health threat."

Fifty nondepressed overweight and obese women between the ages of 24 and 55 were enrolled in the study, the core of which was an eight-week randomized comparison of bupropion with a dummy pill, or placebo, with neither the researcher nor the subject knowing which was the drug and which was the placebo. All women had a body mass index (BMI) between 28.0 and 52.6. A BMI of 25 to 29.9 is considered overweight, while 30 and above is considered obese.

Women who responded to the drug with demonstrated weight loss after eight weeks continued the same treatment in such a double-blind manner for an additional 16-week "continuation phase." Additional single-blind follow-up treatment was done for a total of two years.

Among the participants who completed the first eight weeks, 67% taking bupropion lost more than 5% of their baseline body weight, while only 15% in the placebo group lost more than 5%. During the continuation phase, the 14 bupropion participants who completed 24 weeks achieved an average weight loss of 12.9% of their baseline body weight, with nearly 74% of the weight loss attributed to a loss of fatty tissue.